Skip To Main Content
Illert ALL on Muck Rack

Illert ALL

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Illert

Contact Illert, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Final analysis of the CLL2-GIVe trial (obinutuzumab, ibrutinib, and venetoclax) in untreated CLL with del(17p)/TP53mut

|
By von Tresckow J, Niemann CU, Al-Sawaf O, Illert ALL
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared Issue with article?
See all 1 articles